Azurity Pharmaceuticals v. Annora Pharma: Eight-Patent QBRELIS Dispute Dismissed Without Prejudice
Azurity Pharmaceuticals filed suit against Indian generic manufacturer Annora Pharma in the District of New Jersey, asserting eight patents covering its QBRELIS angiotensin-converting enzyme inhibitor oral solution. After 445 days of litigation, the parties jointly stipulated to dismiss all claims and counterclaims without prejudice, with each side bearing its own costs.
Eight-Patent QBRELIS Battle Ends in Stipulated Dismissal With Retained Jurisdiction
On September 7, 2023, Azurity Pharmaceuticals, Inc. filed this infringement action against Annora Pharma Private Ltd. in the U.S. District Court for the District of New Jersey. The complaint asserted eight issued U.S. patents — US10039800B2, US10265370B2, US9616096B1, US10406199B2, US11179434B2, US9814751B2, US10940177B2, and US9463183B1 — all directed to formulations and methods of use associated with QBRELIS, Azurity’s branded lisinopril oral solution indicated as an angiotensin-converting enzyme (ACE) inhibitor.
The case closed on November 25, 2024, when the parties filed a joint stipulation of dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii), dismissing all claims and counterclaims without prejudice. Each party bears its own attorneys’ fees and costs. Notably, the court retained jurisdiction to enforce any disputes arising under the parties’ settlement agreement, suggesting a negotiated resolution governs the commercial relationship going forward, even though its specific terms are not publicly available.
The 445-day duration — roughly 15 months — is consistent with ANDA-adjacent pharmaceutical disputes that resolve before significant claim construction or expert discovery. The retention of court jurisdiction over a settlement agreement strongly suggests the parties reached a licensing or market-access arrangement rather than a pure walk-away. What drove the specific terms, including any agreed entry date for Annora’s product or royalty arrangements, is not discernible from the public record.
Filing to Dismissed without Prejudice in 445 days
445-day case — typical ANDA pharma disputes run 18–30 months to trial; this resolved in roughly 15 months
Without-prejudice dismissal: what the stipulation means for both parties
Rule 41(a)(1)(A)(ii) dismissal: what ‘without prejudice’ means here
A stipulated dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) requires consent of all parties and takes effect immediately upon filing. ‘Without prejudice’ means Azurity is not barred from refiling claims on these patents against Annora if circumstances change — for example, if a settlement agreement is breached. No court judgment on the merits was entered, so none of the eight patents was adjudicated valid, invalid, or infringed.
No merits adjudicationAzurity preserves all eight patents and retains the right to refile
Because the dismissal is without prejudice, Azurity’s patent portfolio is legally intact. None of the eight asserted patents was invalidated or held unenforceable. The court’s retained jurisdiction over the settlement agreement gives Azurity a rapid enforcement mechanism if Annora violates agreed terms — a meaningful protection for a branded pharmaceutical company guarding a portfolio product against generic entry.
Patents survive; settlement enforceableAnnora avoids an adverse ruling but faces ongoing patent exposure
Annora secured a resolution without any court finding of infringement, and each party bears its own costs. However, the without-prejudice nature of the dismissal means Annora cannot treat the patents as cleared. Any commercial launch of a competing lisinopril oral solution would need to navigate Azurity’s eight-patent portfolio — and breach of the underlying settlement agreement could trigger prompt re-litigation in New Jersey under retained jurisdiction.
No clearance; patents remain activeRetained jurisdiction signals a structured settlement, not a clean break
In pharmaceutical patent disputes, court-retained jurisdiction over a settlement agreement typically signals negotiated terms — often a licensed entry date, royalty, or co-promotion arrangement. For QBRELIS competitors and ACE inhibitor oral solution market participants, this outcome suggests Azurity’s eight-patent portfolio remains a significant barrier to unencumbered generic entry. Companies developing lisinopril oral solution formulations should treat these patents as live enforcement risk.
Structured settlement likelyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Azurity Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of eight QBRELIS lisinopril oral solution patentsSearch in Eureka ↗ |
| Defendant | Annora Pharma Private, Ltd. | Company | Indian generic pharmaceutical manufacturer seeking U.S. market entry with lisinopril oral solutionSearch in Eureka ↗ |
| Plaintiff counsel | Arnold B. Calmann | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katherine Ann Escanlar | Attorney | Counsel for Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saiber LLC | Law Firm | Representing Azurity Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Stephanie-Rose Orlando | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation dismisses all claims and counterclaims without prejudice under Rule 41(a)(1)(A)(ii), meaning no court rendered a judgment on whether any of the eight patents was valid, infringed, or enforceable. The explicit retention of district court jurisdiction to resolve disputes under the parties’ settlement agreement is legally significant — it transforms the court into a standing enforcement tribunal without requiring fresh pleadings, providing Azurity meaningful leverage should Annora deviate from agreed commercial terms.
US10039800B2 and seven further patents — QBRELIS lisinopril oral solution formulations
The eight asserted patents — US10039800B2, US10265370B2, US9616096B1, US10406199B2, US11179434B2, US9814751B2, US10940177B2, and US9463183B1 — collectively protect Azurity’s QBRELIS lisinopril oral solution, an angiotensin-converting enzyme (ACE) inhibitor indicated for hypertension and heart failure. The patents span composition-of-matter, formulation stability, and method-of-use claims, creating a layered patent estate. Application dates span from approximately 2015 through 2021, suggesting an actively prosecuted portfolio designed to extend commercial protection across successive patent expiries.
For generic pharmaceutical manufacturers targeting the lisinopril oral solution market, this eight-patent cluster represents a formidable clearance challenge. Each patent must be independently addressed — whether through design-around, IPR challenge, or negotiated licensing — before an unencumbered launch is feasible. The fact that Azurity pursued litigation to the 15-month mark before settling, combined with the retained court jurisdiction clause, indicates Azurity views this portfolio as a commercially enforced asset, not a defensive filing. Sector participants should monitor continuation filings that may extend coverage further.
Should your team run an FTO against Azurity’s QBRELIS patent portfolio?
Any R&D or regulatory team developing a lisinopril oral solution — whether as an ANDA filer, 505(b)(2) applicant, or private-label manufacturer — should treat Azurity’s eight-patent estate as a live enforcement risk. The portfolio’s breadth across composition, formulation, and method-of-use claims means that designing around one patent does not automatically clear the others. An FTO analysis should be initiated before IND filing, and certainly before any ANDA submission or manufacturing scale-up commitment.
PatSnap Eureka’s FTO Search Agent can map all eight asserted patents — plus their cited prior art, continuation families, and related applications — against your specific lisinopril formulation parameters. Eureka identifies claim-by-claim overlap, surfaces potential design-around opportunities, and flags pending continuations that could extend Azurity’s coverage. For a portfolio this size, automated claim charting and family monitoring significantly reduces the time and cost of a thorough clearance exercise.
Run a freedom-to-operate analysis on US10039800B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical oral solution patent cases in New Jersey District Court
Explore related ANDA-adjacent pharmaceutical formulation patent disputes filed in the District of New Jersey involving ACE inhibitor and oral solution patent portfolios.
What this case signals for the pharmaceutical oral solution IP landscape
Eight patents, one product, and a court-retained settlement enforcement clause — this case carries clear signals for ACE inhibitor generics strategy.
Azurity’s eight-patent cluster creates layered generic entry barriers
Asserting eight patents on a single oral solution product — spanning composition, formulation, and method-of-use claims — is a deliberate portfolio strategy. Challengers must clear all eight to launch freely. Any company developing a competing lisinopril oral solution should conduct a comprehensive FTO analysis across the full patent family before committing to clinical or manufacturing investment.
Retained court jurisdiction is a non-trivial enforcement tool for Azurity
The District of New Jersey’s retained jurisdiction over the settlement agreement means Azurity can enforce breach without filing a new complaint. This lowers the cost and time of re-engaging the court. For Annora, any deviation from agreed commercialization terms risks fast-tracked court action — a significant operational constraint on launch timing and product positioning.
Azurity v Annora — key questions answered
Azurity asserted eight U.S. patents: US10039800B2, US10265370B2, US9616096B1, US10406199B2, US11179434B2, US9814751B2, US10940177B2, and US9463183B1. All eight cover formulations and methods of use relating to QBRELIS, Azurity’s lisinopril oral solution ACE inhibitor product. No court adjudicated the validity or infringement of any of these patents — the case was dismissed without prejudice by stipulation.
The parties filed a joint stipulation under Fed. R. Civ. P. 41(a)(1)(A)(ii) dismissing all claims and counterclaims without prejudice. The court retained jurisdiction over the parties’ settlement agreement, strongly suggesting a negotiated commercial resolution — such as a licensed entry date or royalty arrangement — underlies the dismissal. The specific settlement terms are not publicly available.
No. A without-prejudice dismissal does not constitute a finding that Annora’s product is non-infringing or that Azurity’s patents are invalid. Annora remains subject to all eight asserted patents. Any commercial launch would need to comply with the terms of the confidential settlement agreement, and breach could trigger re-litigation under the court’s retained jurisdiction without a new complaint being required.
Retained jurisdiction means the District of New Jersey can enforce the settlement without requiring the parties to file a new lawsuit. If either party — most practically, if Annora were to launch its product in violation of agreed terms — Azurity could bring a motion before the same court for expedited enforcement. This is a significant practical advantage for the patent holder and a meaningful constraint on Annora’s commercialization flexibility.
QBRELIS is Azurity Pharmaceuticals’ branded lisinopril oral solution, an ACE inhibitor used to treat hypertension and heart failure. Multi-patent protection on a single drug product is a common branded pharmaceutical strategy: separate patents cover composition of matter, formulation stability, dosing methods, and manufacturing processes, with staggered expiry dates. This portfolio architecture forces generic challengers to clear every patent independently, raising the cost and complexity of market entry.
PatSnap Eureka searches patents and litigation data to answer instantly.